For research use only. Not for therapeutic Use.
(±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research[1].
| Catalog Number | R005543 |
| CAS Number | 6493-06-7 |
| Synonyms | 1-(5-hydroxyhexyl)-3,7-dimethylpurine-2,6-dione |
| Molecular Formula | C13H20N4O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3 |
| InChIKey | NSMXQKNUPPXBRG-UHFFFAOYSA-N |
| SMILES | CC(CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C)O |
| Reference | [1]. Yang Z, et al. Lisofylline: a potential lead for the treatment of diabetes. Biochem Pharmacol. 2005 Jan 1;69(1):1-5. |
